Study of DF6215 in Patients With Advanced Solid Tumors
Phase 1 Completed
35 enrolled
Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Phase 1 Completed
62 enrolled 17 charts
Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer
Phase 1 Completed
15 enrolled
Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors
Phase 1 Completed
21 enrolled
A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers
Phase 1 Completed
42 enrolled
Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors
Phase 1 Completed
18 enrolled
Endoxifen in Adults With Hormone Receptor Positive Solid Tumors
Phase 1 Completed
40 enrolled
Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers
Phase 1 Completed
86 enrolled 17 charts
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903
Phase 1 Completed
69 enrolled
A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors
Phase 1 Completed
6 enrolled
A Trial Evaluating TG4050 in Ovarian Carcinoma.
Phase 1 Completed
64 enrolled 14 charts
Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Primary Ovarian or Uterine Cancer
Phase 1 Completed
15 enrolled
Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Phase 1 Completed
83 enrolled 21 charts
AMPLIFY-201
Phase 1 Completed
25 enrolled 15 charts
TRAMUNE
Phase 1 Completed
40 enrolled 23 charts
Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers
Phase 1 Completed
136 enrolled
CNSI-Fe(II)
Phase 1 Completed
19 enrolled 47 charts
Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
Phase 1 Completed
23 enrolled
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
Phase 1 Completed
54 enrolled
Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
Phase 1 Completed
285 enrolled
Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer
Phase 1 Completed
16 enrolled 14 charts
Doxil/Caelyx BE Study
Phase 1 Completed
36 enrolled
Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer
Phase 1 Completed
3 enrolled
Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis
Phase 1 Completed
26 enrolled
Continued Access to RXDX-105
Phase 1 Completed
3 enrolled
CAR T Cells in Mesothelin Expressing Cancers
Phase 1 Completed
65 enrolled 14 charts
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Phase 1 Completed
58 enrolled
Molecular Imaging of EpCAM Receptors Using [123I]I-DARPIN-Ec1
Phase 1 Completed
10 enrolled
Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer
Phase 1 Completed
9 enrolled
BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer
Phase 1 Completed
19 enrolled 21 charts
Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Phase 1 Completed
25 enrolled
Phase 1 Dose Escalation of ArtemiCoffee
Phase 1 Completed
13 enrolled
ACTolog
Phase 1 Completed
38 enrolled
Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer
Phase 1 Completed
27 enrolled 21 charts
A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers
Phase 1 Completed
112 enrolled
Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer
Phase 1 Completed
26 enrolled
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
Phase 1 Completed
121 enrolled
Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations
Phase 1 Completed
10 enrolled
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
Phase 1 Completed
12 enrolled
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
Phase 1 Completed
279 enrolled
OVAR
Phase 1 Completed
42 enrolled
Study of Continuous OSI-906 Dosing
Phase 1 Completed
95 enrolled
IVY
Phase 1 Completed
353 enrolled
Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
Phase 1 Completed
29 enrolled
A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors
Phase 1 Completed
190 enrolled
Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer
Phase 1 Completed
35 enrolled 16 charts
PEMBOV
Phase 1 Completed
47 enrolled
A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors
Phase 1 Completed
73 enrolled 18 charts
Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.
Phase 1 Completed
32 enrolled 37 charts
Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase 1 Completed
24 enrolled